These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29943693)

  • 1. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex
    Koscielny V
    Neurodegener Dis Manag; 2018 Jun; 8(3):141-142. PubMed ID: 29943693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA;
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J; Schippling S; Montalban X; Kappos L; Cree BAC; Comi G; Arnold DL; Hartung HP; Sheffield JK; Liu H; Silva D; Cohen JA
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
    Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
    Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
    Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A
    CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
    Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
    Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.